Darapladib Ineffective for Secondary Prevention After Acute Coronary Events

In SOLID-TIMI 52, the drug performed no better in patients with unstable disease than it had in those with stable disease.

Darapladib is an investigational selective oral inhibitor of lipoprotein-associated phospholipase A2, an inflammatory-pathway mediator associated with elevated cardiovascular risk. In the STABILITY trial, darapladib failed to improve clinical outcomes in patients with stable coronary artery disease (NEJM JW Cardiol Mar 30 2014). Now, investigators have assessed the efficacy and safety of darapladib in patients with an acute coronary syndrome (ACS).

SOLID-TIMI 52 (NCT01000727) was a manufacturer-funded, double-blinded, randomized trial involving 13,026 patients in 36 countries. Within 30 days after hospitalization for an ACS, participants were assigned to receive once-daily darapladib (160 mg) or placebo in addition to guideline-based therapy…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

Darapladib Ineffective for Secondary Prevention After Acute Coronary Events

Topics

Reviewing Author